Our customers continually publish their research into a huge range of subjects. Here we present selected publications, highlighting research using our Pro5® MHC Class I Pentamers in applications such as flow cytometry, separation of antigen-specific T cells with magnetic beads and intracellular cytokine staining.
A comprehensive list of customer publications is available here, and is frequently updated.
Immunovaccine Inc., Nova Scotia, Canada Liposomes deliver an immune hit to cancer cells
Marcus Butler, Dana Farber Cancer Center, USA Killer T Cells Trained for Long-lasting Anti-Cancer Effects
John Webb, British Columbia Cancer Agency, Canada High-grade ovarian cancer: MHC Pentamers are used to investigate immunotherapy prospects.
Ingerid Abrahamsen, Oslo University Hospital, Oslo Norway Allogeneic T cells may be targeted to B cell leukemia
Erlend Stronen, Radiumhospitalet, Norway Pentamers identify allo-restricted T cells in study to advance research into cancer immunotherapy
Maxim Pavlenko, Karolinska University Hospital, Sweden Epitope discovery in prostate cancer: characterizing an immunodominant CTL epitope of PSA in mice.
James Wells, King’s College London, UK New adjuvant drives unprecedented cytotoxic T cell response providing a potent vaccine development platform
Hiro Yagi, Hamamatsu University School of Medicine, Japan Pro5® Pentamers integral in successful research into novel immunization strategy
Paul Moss, University of Birmingham, UK Pro5® Pentamers are used to enrich CMV-specific T cells for transfusion into transplant patients
Stephanie Gras, Queensland Institute of Medical Research, Australia Analysing allelic polymorphism in the T cell receptor and its impact on immune responses in an EBV setting
Judy Tellam, Queensland Institute of Medical Research, Australia Pro5® MHC Class I Pentamer combined with intracellular cytokine staining shows how protein translation affects the molecular dynamics of antigen presentation
Christopher Fox, University of Birmingham, UK Researchers use Pro5® MHC Pentamers to identify an exciting new target for EBV treatment
Michael Uhlin, Karolinska Institute, Sweden Pro5® Pentamers central in life-saving procedure for PTLD treatment
Suzanne Elliot, Queensland Institute of Medical Research, Australia Pro5® MHC Class I Pentamers used to evaluate vaccine safety
Adam Gehring, Singapore Institute for Clinical Science, Singapore Phenotypic analysis of HBV-specific T cells using Pro5® Pentamers
Victoria Kasprowicz, University of KwaZulu Natal, South Africa A story of viral escape through sequence variation in chronic Hepatitis C Virus infection
Lars Frelin, Karolinska Institute, Sweden Developing a therapeutic Hepatitis B Vaccine with Pro5® Pentamers
Ellie Barnes, University of Oxford, UK Success for Hepatitis C Vaccine Trials at Oxford University
Jorge Almeida, INSERM, France T cell vaccines for HIV-1 move a step closer – researchers use HIV-specific Pro5® MHC Class I Pentamers combined with intracellular cytokine staining
Aude Chapuis, Fred Hutchinson Cancer Research Center, USA Sending in trained killers to attack residual HIV infection
Ana Ferreira, Instituto Gulbekian de Ciência, Portugal Researchers show how inheritance of Sickle Cell Anemia protects against Malaria infection
J Guo, University of Texas, USA Deletion of FoxN1 in the thymic medullary epithelium reduces peripheral T cell responses to infection and mimics changes of aging
Roberto Mallone, Hôpital Saint Vincent de Paul, France How does blood processing affect the results of cell-mediated immunity assays? ProImmune’s Flu Pro5® MHC Class I Pentamer is used as an exemplar in an exploratory study
Suryaprakash Sambhara, Centre for Disease Control and Prevention CDC, USA Study on H5N1 vaccine uses Pro5® Pentamer to correlate immune response with protection
Sam Behar, Harvard Medical School, USA A Messy End for TB-infected Macrophages
Bruce Blazar, University of Minnesota, USA In Situ Identification of Allospecific B Cells using Pentamers
Back to top
